{"id":4252,"date":"2024-05-30T17:30:58","date_gmt":"2024-05-30T21:30:58","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/"},"modified":"2026-09-24T00:05:51","modified_gmt":"2026-09-24T04:05:51","slug":"gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/","title":{"rendered":"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 30 mai 2024, 19:30 CEST<\/strong> \u2013 L\u2019Assembl\u00e9e G\u00e9n\u00e9rale Mixte des actionnaires de la soci\u00e9t\u00e9 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, s\u2019est r\u00e9unie le 29 mai 2024 \u00e0 9h00 au si\u00e8ge social de la Soci\u00e9t\u00e9, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France, sous la pr\u00e9sidence de Laurence Rodriguez, Directrice G\u00e9n\u00e9rale de la Soci\u00e9t\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Toutes les r\u00e9solutions recommand\u00e9es par le Conseil d\u2019Administration et soumises \u00e0 l\u2019Assembl\u00e9e g\u00e9n\u00e9rale mixte ont \u00e9t\u00e9 adopt\u00e9es \u00e0 l\u2019exception des r\u00e9solutions A et B qui ont \u00e9t\u00e9 rejet\u00e9es, conform\u00e9ment aux recommandations du Conseil d\u2019administration. Le quorum r\u00e9uni sur premi\u00e8re convocation s\u2019est \u00e9tabli \u00e0 46.81%.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le r\u00e9sultat du scrutin par r\u00e9solution est disponible sur le site internet de la Soci\u00e9t\u00e9 dans la rubrique Investisseurs (<a href=\"https:\/\/www.gensight-biologics.com\/fr\/investisseurs-media\/\">www.gensight-biologics.com\/fr\/investisseurs-media\/<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 30 mai 2024, 19:30 CEST \u2013 L\u2019Assembl\u00e9e G\u00e9n\u00e9rale Mixte des actionnaires de la soci\u00e9t\u00e9 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, s\u2019est r\u00e9unie [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[85],"news-type":[82],"post-year":[],"class_list":["post-4252","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-general-meeting","news-type-general-meeting"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 30 mai 2024, 19:30 CEST \u2013 L\u2019Assembl\u00e9e G\u00e9n\u00e9rale Mixte des actionnaires de la soci\u00e9t\u00e9 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, s\u2019est r\u00e9unie [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-30T21:30:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:51+00:00\" \/>\n<meta name=\"author\" content=\"Emmanuelle Lopez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emmanuelle Lopez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/\"},\"author\":{\"name\":\"Emmanuelle Lopez\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/1ea9b27acac405517389dca417e5eed6\"},\"headline\":\"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte\",\"datePublished\":\"2024-05-30T21:30:58+00:00\",\"dateModified\":\"2026-09-24T04:05:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/\"},\"wordCount\":208,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/\",\"name\":\"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2024-05-30T21:30:58+00:00\",\"dateModified\":\"2026-09-24T04:05:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/1ea9b27acac405517389dca417e5eed6\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/05\\\/30\\\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/1ea9b27acac405517389dca417e5eed6\",\"name\":\"Emmanuelle Lopez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g\",\"caption\":\"Emmanuelle Lopez\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/","og_locale":"fr_FR","og_type":"article","og_title":"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte - GenSight Biologics","og_description":"Paris, France, le 30 mai 2024, 19:30 CEST \u2013 L\u2019Assembl\u00e9e G\u00e9n\u00e9rale Mixte des actionnaires de la soci\u00e9t\u00e9 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, s\u2019est r\u00e9unie [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/","og_site_name":"GenSight Biologics","article_published_time":"2024-05-30T21:30:58+00:00","article_modified_time":"2026-09-24T04:05:51+00:00","author":"Emmanuelle Lopez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Emmanuelle Lopez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/"},"author":{"name":"Emmanuelle Lopez","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/1ea9b27acac405517389dca417e5eed6"},"headline":"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte","datePublished":"2024-05-30T21:30:58+00:00","dateModified":"2026-09-24T04:05:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/"},"wordCount":208,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/","name":"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2024-05-30T21:30:58+00:00","dateModified":"2026-09-24T04:05:51+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/1ea9b27acac405517389dca417e5eed6"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/05\/30\/gensight-biologics-annonce-lapprobation-de-lensemble-des-resolutions-soutenues-par-le-conseil-dadministration-lors-de-son-assemblee-generale-mixte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Gensight Biologics annonce l\u2019approbation de l\u2019ensemble des r\u00e9solutions soutenues par le Conseil d\u2019administration lors de son assembl\u00e9e g\u00e9n\u00e9rale mixte"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/1ea9b27acac405517389dca417e5eed6","name":"Emmanuelle Lopez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g","caption":"Emmanuelle Lopez"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4252"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4252\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4252"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4252"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4252"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4252"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}